健康元

1 1
2 2
3 3
关于我们

ABOUT US 

Joincare (Joincare Pharmaceutical Group Industry Co., Ltd) is headquartered in Shenzhen. After years of steady operation and rapid development, it has now become an innovative and scientific research-oriented comprehensive pharmaceutical group. The company has always adhered to technological innovation as its strategic basis, and its strategic goal is to build a high-barrier complex preparation technology platform. Currently, it has deployed four high-barrier complex preparation R&D platforms. It owns two large listed companies of Joincare and Livzon Pharmaceutical, more than 20 major holding subsidiaries, and currently employs nearly 13,000 people. As of the end of 2020, the company's total assets were 28.157 billion yuan and operating income was 13.522 billion yuan.

More

NEWS

14
2022/03

Joincare's COVID-19 vaccine booster that can effectively fight against Omicron is under application for marketingJoincare's COVID-19 vaccine booster that can effectively fight against Omicron is under application for marketing

How to improve the resistance against the Omicron variant on the basis of existing COVID-19 vaccines? Sequential booster immunization (also known as "heterologous booster vaccination") is regarded as one of the important exploration directions.
16
2021/03

The Inhale Preparation of Joincare is Listed in the Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease

The Guideline for Diagnosis and Management of Chronic Obstructive Pulmonary Disease in 2001 (‘the new guideline’ in the following passages) has been released recently. Lishutong (Levosalbutamol Hydrocloride Nebuliser Solution), a product Joincare Pharmaceutical Group Industry Co., Ltd (Joincare), is the first authorized β2 adrenoceptor agonist. The medicine was recommended as the first-line treatment. All of these is a sign that the high-standard inhale preparation formally join in the market competition.
31
2020/08

Exploring the Blue Ocean Market of Inhalation Industry!Two Major Products Developed by Joincare Were Permitted to Produce

In the evening of 24th, Aug., Joincare Pharmaceutical Group Industry Co., Ltd (Joincare) has released the public notification that the company gained the ‘Drug Production License’ (DPL). Until now, the two major combination medicinal products developed by Joincare, Compound Ipratropium Bromide Solution for Inhalation and Levosalbutamol Hydrochloride Nebuliser Solution, have begun to be manufactured.
10
2020/12

Action Speaks for Responsibility, Joincare Wins Best Social Responsibility Award of "China ESG Golden Awards 2020"

The "Environment, Social Responsibility and Corporate Governance (ESG) Summit of Sina Golden Kirin Forum 2020", sponsored by finance.sina.com.cn, was held in the building of the Sina headquarters in Beijing on December 8. Under the theme of "Implementing an ESG Philosophy to Achieve the Sustainable Development Goals", this summit invited a number of excellent listed companies, institutional investors and authoritative media to bring together upstream and downstream resources of industrial development, connect ideas and resources, and unleash value and strength.  
11
2020/12

Budesonide Suspension (Big Specification) Approved, Joincare Establishes Inhalable Drug Matrix

News from Cailian Press (Shenzhen, Reporter: Ding Rong): Joincare Pharmaceutical Group Industry Co., Ltd. (Joincare, 600380.SH) has seen new progress in its high-profile Budesonide Suspension for Inhalation. The Company recently received the Drug Registration Certificate issued by the National Medical Products Administration (NMPA) for its drug named Budesonide Suspension for Inhalation (generic name), according to the announcement released by Joincare on the evening of December 10. A number of the Company's inhalable drugs have been approved, and this Budesonide Suspension for Inhalation (big specification) is projected to be a core product with a large market volume in line with its deployment at the early stage, a manager from Joincare told Cailian Press on the morning of December 11.
17
2020/09

Joincare leads the breathing layout and releases intrinsic value, many institutions are optimistic about its future

According to the latest information, on September 3, 2020, the official website of National Medical Products Administration showed that Joincare (600380) was approved to produce ipratropium bromide inhalation solution in application of imitated Category IV, which was the first in China to pass the consistency evaluation. Up to now, Joincare has already been approved for production of many kinds of inhalants, such as ipratropium bromide inhalation solution, budesonide suspension for inhalation, compound ipratropium bromide inhalation solution and levalbuterol hydrochloride inhalation solution, which have been considered as evaluated. Among them, levalbuterol hydrochloride inhalation solution fills in the blank domestic market.
23
2020/09

The fifth session of Pengcheng Charitable Donation List was published, and Joincare’s Chairman Zhu Baoguo was selected into the personal list of charitable donation

In the morning of September 19, on the eighth session of the exchange and exhibition meeting of Chinese public charity projects, “the Fifth Session of Pengcheng Charity Award and 2019 Shenzhen Charitable Donation List Release Conference” was held in Meihua Hall of Shenzhen Convention & Exhibition Center grandly. 119 persons, enterprises, institutions and projects won this award. Zhu Baoguo, Chairman of Joincare Pharmaceutical Group Industry Co., Ltd., once again selected into “Pengcheng Charitable Donation Personal List” of Shenzhen Pengcheng Charitable Award due to his outstanding contributions in the field of public charities.
17
2020/11

Giving full play to the advantages of pharmaceutical health industry, Joincare has been awarded “Outstanding Contribution Award of Anti-epidemic”

On November 16, “the Best Listed Companies in Greater China in 2020” award ceremony hosted by Gelonghui was grandly held in Chengdu. Through screening layer by layer, Joincare Pharmaceutical Group Industry Co., Ltd. won “Outstanding Contribution Award of Anti-epidemic” from many candidate enterprises.
More

OUR BUSINESS

SEARCH FOR THE PRODUCTS YOU NEED

Search
投资者关系

Corporate Social Responsibility

More
工作机会

Investor Relations

More
企业社会责任

Job Opportunities

More

Quick Navigation

Service Hotline

Service

Hotline

Copyright © Joincare Pharmaceutical Group Industry Co., Ltd. All Rights Reserved.  Powered by:www.300.cn Zhuhai  粤ICP备14024104号